Export USA Webinar Series Opportunities for Canadian Businesses in the U.S. Health IT Market

INVITATION ALUMNI BREAKFAST SPEAKER SERIES

The University of Ottawa Telfer School of Management

is pleased to invite you to the next BioTech themed breakfast.

 

 James Pelot

 Chief Financial Officer, ArcticDX

 

 

Discussing:

 

“From Bench to Box - a genetic testing biotech start-up journey”

 

 

Date:              Wednesday, November 25, 2009

 

Time:             7:00 a.m.                     Coffee and networking

7:30 a.m.                     Breakfast

8:00 a.m. – 9:00 a.m.   Presentation

 

Location:       Telfer School of Management

                       Desmarais Building, Room 4101, 4^th Floor

55 Laurier E., Ottawa ON, K1N 6N5

                       (“Pay and Display” parking available under Desmarais Building)

                       OC Transpo: Laurier Station

 

Price:             $30 per person

$20 for uOttawa students and alumni

          

RSVP:            Before November 23, 2009 - Register early. Seats are limited.

(Payable in advance by MasterCard, Visa, cash or cheque.)

No-shows will be billed.  Substitutions are allowed at any time.

 

Register online:        

http://www.alumboutique.ca/  (Click English, Events, Ottawa Area Events)

 

Contact us:                Tel.: (613) 562-5800 x 2396  

Fax: (613) 562-5332

alumni@telfer.uOttawa.ca

Biography

Mr. James Pelot

Chief Financial Officer,

ArcticDX

 

Mr. Pelot was Chief Financial Officer and Chief Operating Officer of Tm Bioscience Corporation until March of 2007. Tm Bioscience (now Luminex Molecular Diagnostics) is a leader in the field of development, manufacturing and commercialization of genetic tests. From his appointment in September 2001, Mr. Pelot was responsible for the development of the Company’s infrastructure, securing capital, investor relations and financial reporting. Mr. Pelot’s key accomplishments include raising in excess of $75 million in funds from public, private and governmental sources; graduating the Company to the TSX from the TSX – Venture stock exchange and registering the Company as a reporting issuer in the U.S. Prior to joining Tm Bioscience, Mr. Pelot was a co-founder of a wireless internet company acquired by InfoSpace and served in various executive roles within sales, marketing and finance both there and at Nortel Networks Limited. Mr. Pelot holds a B. Commerce degree from the University of Ottawa and is a Chartered Accountant.

 

Event partners: CATA, Ottawa Business Journal, uOttawa Faculty of Science

International Swine Flu Conference, November 23-24, 2009 in Toronto, Canada

Top leaders and key decision-makers of major companies representing a broad range of industries will meet with distinguished scientists, public health officials, law enforcers, first responders, and other experts to discuss pandemic prevention, preparedness, response and recovery at the 1st International Swine Flu Conference.

At the International Swine Flu Conference, attendees will be able to draw on first-hand best practices to create the solid business continuity plans that their companies and organizations need in order to prepare for, respond to, and survive a pandemic.

The International Swine Flu Conference draws on the success of the seven previous Bird Flu summits which featured as speakers several distinguished personalities such as Dr. David Nabarro, the United Nations Coordinator for Avian and Human Influenza, Alex Thiermann of the World Organization for Animal Health (OIE) and Dr. Wenqing Zhang of the WHO Epidemic and Pandemic Alert and Response.

For more information or to register visit http://new-fields.com/isfc_canada/

OCRI Announces Call for Nominations for 2010 OCRI Awards

2010 OCRI Awards now accepting nominations. Deadline to apply is December 4 2009.

PLEASE NOTE: Life Science and cleantech companies are eligible for all award categories. The Health Innovation and Research awards have been carried over from the Life Sciences Awards. We encourage all life science and cleantech companies to browse the available award categories and submitt a nomination.

RECOGNITION • EXPOSURE • OPPORTUNITY

The OCRI Awards are synonymous with business excellence in the Ottawa region, shining a spotlight on the people and innovation that set the standard and serve as role models in our region. With three new awards, the 2010 OCRI Awards will recognize the most innovative individuals, teams and organizations who have contributed to Ottawa’s knowledge-based community by way of research, technology, entrepreneurship, leadership, partnerships and student accomplishment. The OCRI Awards dinner is the largest and most inclusive knowledge-based industry event in Ottawa, involving all sizes and sectors of Ottawa’s knowledge-based companies.

Those who participate in the OCRI Awards benefit through:

• Recognition as a leading knowledge-based company or individual who demonstrates extraordinary excellence. Set yourself apart from the competition and become a 2010 OCRI Award Finalist or Winner!
• Exposure via media distribution channels and the marketing and communications program delivered by OCRI to showcase all the finalists and winners.
• Opportunity to capture the eye of many industry observers as a recognized OCRI Award finalist. Investors look for quality assurance and quality knowledge-based talent dream of working for companies that inspire innovation. Give them the reason they need to keep your company at the forefront of consideration.

Three finalists will be chosen from each category. The winner will be announced at the Awards Dinner on April 8, 2010 at the Hilton Lac-Leamy.

For more information please visit http://www.ocri.ca/awards/

BiOS and Photonics West Jan 2010 - Exhibit in Canadian Pavilion

The Ottawa Photonic Cluster, in collaboration with the Canadian Photonics Consortium, the Canadian Photonics Fabrication Centre, and the Quebec Photonic Network are co-organizing a Canadian Pavilion at the BiOS Exhibition 2010 (January 23-24) and the Photonics West Exhibition 2010 (January 26-28) which both will be held at the Moscone Center located in San Francisco California.

BiOS is the world’s largest and most prestigious international biomedical optics and imaging conference, encompassing clinical, translational, and fundamental R&D.  BiOS provides you with a premier technical forum for reporting your achievements and learning about the latest clinical and technical advances. BiOS is a major impetus for launching new applications and technologies; patent citations indicate the importance of the research introduced in these conferences.

http://www.ottawaregion.com/_news/news_1464.php

MEDEC’s Legal & Regulatory Conference - Toronto - Oct 28/29

MEDEC’s not to be missed annual legal and regulatory learning and networking event!  Features public and private industry experts speaking and engaging in interactive workshops outlining future regulatory strategies as they will apply to medical devices and emerging technologies across Canadian jurisdictions.

http://www.medec.org/events_and_programs

University of Ottawa researchers elected to the Royal Society of Canada

OTTAWA, September 28, 2009 — Xiaoyi Bao and Annie Brisset, researchers at the University of Ottawa, have been elected fellows of the Royal Society of Canada (RSC) in recognition of their exceptional achievements in the areas of sciences and arts and humanities, respectively.

Xiaoyi Bao, a professor in the Department of Physics at the Faculty of Science, holds the Canada Research Chair in Fibre Optics and Photonics. Her research interests include high-speed transmission systems using fibre optics. Bao and her team are working to develop a sensor that can measure the temperature and soundness of large structures like buildings, duct systems and oil wells in order to detect any wear in the structure’s fibre optics.

Annie Brisset is a professor at the School of Translation and Interpretation and the Department of Theatre. She is also a consultant to UNESCO on the development of multilingual communication and is a founding member of the International Association for Translation and Intercultural Studies (IATIS). Her areas of interest include sociology and sociocritique of translation, translation theories and discourse theories.

http://www.media.uottawa.ca/mediaroom/news-details_1737.html

The $78.3 Billion Canadian Bio-based Economy

Biotechnology is driving an economic shift to a broader “bio-based economy” which integrates biologic products and technologies, derived from renewable resources into new sustainable production and manufacturing processes.

Canada’s bio-based economy is valued at 78.3 billion dollars. At 6.4 percent of the GDP, this footprint is larger than the automotive and aerospace sectors respectively.

The concept of the bio-based economy goes beyond the traditional definition of biotechnology. The bio-based economy focuses on biological tools and products from renewable resources to create wealth and sustainability in the production of medical treatments, diagnostics, more-nutritional foods, energy, chemicals, and materials, while improving the quality of the environment.

Visit www.beyondmooseandmountains.ca to learn more and take part in the campaign.

BIOTECanada’s Biotechnology Timeline

Beginning in 8,000 BC with the domestication of plant crops and livestock, the Biotechnology Timeline will take you through the decades of biotechnology development worldwide, and in Canada.

From Quebec City and Jean Talon’s brewery using yeast and fermentation technology in the 1660s, to the first reference of biotechnology in print in 1919, to Canada’s role in agriculture, industrial and health care developments to 2006, the Biotechnology Timeline illustrates how biotech research and discovery has taken off.

The timeline is available from BIOTECanada’s website. http://www.imagenenation.ca/pdfs/e-biotimeline.pdf

Biotechnology Partnering Initiative - BioWindhover’s Therapeutics Area Partnering Conference

BIOTECanada and the Consulate General of Canada in Boston would like to invite you to participate in the upcoming Biotechnology Partnering Initiative, which is open to Canadian biotechnology companies and takes place in partnership with BioWindhover’s Therapeutics Area Partnering Conference http://www.tapartnerships.com/content/Main.aspx in Boston, November 17-19, 2009.  The Initiative is limited to 10 Canadian biotechnology companies with therapeutic compounds in the preclinical or clinical phase of development in one or more of the following areas:  

• oncology
• cardiovascular
• metabolic
• neuroscience
• inflammation/auto-immune

Canadian companies who apply to participate and are accepted will be entitled to the following benefits:

• reduced registration to the BioWindhover Conference of US$1395 (a $400 savings). This well attended Conference offers workshops, networking opportunities, panel sessions on Therapeutic Alliances and Dealmaking, and presentations by top companies in the therapeutic areas who have been chosen by BioWindhover; attendees include executives from Merck, Biogen Idec, Bristol-Myers Squibb, Millennium: The Takeda Oncology Company, GlaxoSmithKline, Novartis and Genzyme.  
• one-on-one coaching in preparation for the event and for partnering meetings from professional consultants experienced in running companies, funding companies and advising biotechnology companies, and making pitches to global investors and companies; 
• the arrangement of a minimum of three one-on-one meetings with venture capitalists, angels, or technology partners from Pharma, the biotechnology or medical device industry, who are based in the Boston area or attending the BioWindhover Conference.  The consultant will work with you to identify the best meetings to meet your needs. If you have identified organizations of interest, the consultant can work to get you connected. Also, the consultant will make recommendations.  Local venture capital firms that invest in life sciences include: MPM Healthcare, Oxford Bioscience, VIMAC, Clarus Ventures, Seaflower, among others.  The Boston area is also home to corporate venture funds, including those at Novartis, Genzyme and Biogen Idec.  The well connected local consulting firm has been engaged by Foreign Affairs and International Trade Canada through the Consulate General in Boston.   
• participation in an invitation-only dinner on Tuesday, November 17, with venture capitalists, angels, biotechnology and pharma industry executives  who would be of interest to the Canadian companies participating in the Initiative;

There is no additional charge for participation in this program; however, you must send your profile to Christine Sarkisian, Business Development Officer at the Consulate General of Canada in Boston via email by October 5, 2009.  If accepted, companies must designate a specific executive from the firm who will participate in the Initiative and will communicate with the Consultant in order to ensure a productive program.

This program is being organized by the Consulate General of Canada in Boston in cooperation with BIOTECanada. It is funded by Foreign Affairs and International Trade Canada’s Technology Partnering Program and BIOTECanada.

If connecting with potential R&D partners or raising capital would benefit your company and you would like to participate in this mission, please reply promptly with your profile.  You will be notified as to the status of your acceptance by October 9, 2009. 

If you have any questions on this Initiative, please contact: 

Christine Sarkisian
Business Development Officer
Consulate General of Canada
3 Copley Place, Suite 400
Boston, MA  02116  U.S.A.

Cell: 617-794-3197
Tel: 617-262-3760 x3360
Fax: 617-262-3415

christine.sarkisian@international.gc.ca